Is SUV Corrected for Lean Body Mass Superior to SUV of Body Weight in 68Ga-PSMA PET/CT?

Objectives: This study aimed to investigate the relationship between the standard uptake value (SUV) of body weight and SUV corrected for lean body mass (SUL) parameters obtained from the prostate gland in gallium-68 (68Ga)-prostate-specific membrane antigen (PSMA) positron emission tomography-computed tomography (PET/CT) with Gleason grade (GG) groups, D’Amico risk groups, and presence of metastases. Methods: Patients with prostate adenocarcinoma who underwent 68Ga-PSMA PET/CT for staging at our center between February 2017 and October 2018 were evaluated retrospectively. Maximum SUV(SUVmax), SUVpeak, SULmax, SULpeak, SUVmean, and SULmean values of the prostate tumor were obtained. The difference in these values between GG groups (≥3,

68Ga PSMA PET/BT’de Yağsız Vücut Kütlesine Göre Düzeltilmiş SUV Vücut Ağırlığına Göre Hesaplanan SUV’den Daha mı Üstün?

Amaç: Amacımız, galyum-68 (68Ga)-prostat spesifik membran antijeni (PSMA) pozitron emisyon tomografisi-bilgisayarlı tomografide (PET/BT) prostat bezinden elde edilen standart uptake değeri (SUV) ve yağsız vücut kütlesine göre düzeltilmiş SUV (SUL) parametrelerinin Gleason grade (GG) grupları, D’Amico risk grupları, metastaz varlığı değerlendirmedeki ilişkilerinin araştırılmasıdır. Yöntem: Merkezimizde Şubat 2017-Ekim 2018 tarihleri arasında prostat adenokarsinomu tanısı ile evreleme amaçlı 68Ga-PSMA PET/BT görüntülemesi yapılan hastalar retrospektif olarak değerlendirildi. Prostat bezinde görülen tümörden SUVmaks, SUVpeak, SULmaks, SULpeak, SUVmean ve SULmean değerleri elde edildi. GG grupları (≥3,

Kaynakça

1. O JH, Lodge MA, Wahl RL. Practical PERCIST: A Simplified Guide to PET Response Criteria in Solid Tumors 1.0. Radiology 2016;280:576-584.

2. Li X, Rowe SP, Leal JP, Gorin MA, Allaf ME, Ross AE, Pienta KJ, Lodge MA, Pomper MG. Semiquantitative Parameters in PSMA-Targeted PET Imaging with 18F-DCFPyL: Variability in Normal-Organ Uptake. J Nucl Med 2017;58:942-946.

3. Sheikhbahaei S, Wray R, Young B, Mena E, Taghipour M, Rahmim A, Subramaniam RM. 18F-FDG-PET/CT therapy assessment of locally advanced pancreatic adenocarcinoma: impact on management and utilization of quantitative parameters for patient survival prediction. Nucl Med Commun 2016;37:231-238.

4. Keyes JW Jr. SUV: standard uptake or silly useless value? J Nucl Med 1995;36:1836-1839.

5. Lee JR, Madsen MT, Bushnel D, Menda Y. A threshold method to improve standardized uptake value reproducibility. Nucl Med Commun 2000;21:685-690.

6. Ramos CD, Erdi YE, Gonen M, Riedel E, Yeung HW, Macapinlac HA, Chisin R, Larson SM. FDG-PET standardized uptake values in normal anatomical structures using iterative reconstruction segmented attenuation correction and filtered back-projection. Eur J Nucl Med 2001;28:155- 164.

7. Sugawara Y, Zasadny KR, Neuhoff AW, Wahl RL. Reevaluation of the standardized uptake value for FDG: variations with body weight and methods for correction. Radiology 1999;213:521-525.

8. Perner S, Hofer MD, Kim R, Shah RB, Li H, Möller P, Hautmann RE, Gschwend JE, Kuefer R, Rubin MA. Prostate-specific membrane antigen expression as a predictor of prostate cancer progression. Hum Pathol 2007;38:696-701.

9. Afshar-Oromieh A, Malcher A, Eder M, Eisenhut M, Linhart HG, Hadaschik BA, Holland-Letz T, Giesel FL, Kratochwil C, Haufe S, Haberkorn U, Zechmann CM. PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging 2013;40:486- 495.

10. Eiber M, Maurer T, Souvatzoglou M, Beer AJ, Ruffani A, Haller B, Graner FP, Kübler H, Haberkorn U, Eisenhut M, Wester HJ, Gschwend JE, Schwaiger M. Evaluation of Hybrid 68Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy. J Nucl Med 2015;56:668-674.

11. Rahbar K, Weckesser M, Huss S, Semjonow A, Breyholz HJ, Schrader AJ, Schäfers M, Bögemann M. Correlation of Intraprostatic Tumor Extent with 68Ga-PSMA Distribution in Patients with Prostate Cancer. J Nucl Med 2016;57:563-567.

12. Gafita A, Calais J, Franz C, Rauscher I, Wang H, Roberstson A, Czernin J, Weber WA, Eiber M. Evaluation of SUV normalized by lean body mass (SUL) in 68Ga-PSMA11 PET/CT: a bi-centric analysis. EJNMMI Res 2019;9:103.

13. D’Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, Tomaszewski JE, Renshaw AA, Kaplan I, Beard CJ, Wein A. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998;280:969-974.

14. Rowe SP, Pienta KJ, Pomper MG, Gorin MA. PSMA-RADS Version 1.0: A Step Towards Standardizing the Interpretation and Reporting of PSMAtargeted PET Imaging Studies. Eur Urol 2018;73:485-487.

15. Janmahasatian S, Duffull SB, Ash S, Ward LC, Byrne NM, Green B. Quantification of lean bodyweight. Clin Pharmacokinet 2005;44:1051- 1065.

16. Tahari AK, Chien D, Azadi JR, Wahl RL. Optimum lean body formulation for correction of standardized uptake value in PET imaging. J Nucl Med 2014;55:1481-1484.

17. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors. J Nucl Med 2009;50 Suppl 1:122S-150S.

18. Uprimny C, Kroiss AS, Decristoforo C, Fritz J, von Guggenberg E, Kendler D, Scarpa L, di Santo G, Roig LG, Maffey-Steffan J, Horninger W, Virgolini IJ. 68Ga-PSMA-11 PET/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumour. Eur J Nucl Med Mol Imaging 2017;44:941-949.

19. Ergül N, Yilmaz Güneş B, Yücetaş U, Toktaş MG, Çermik TF. 68GaPSMA-11 PET/CT in Newly Diagnosed Prostate Adenocarcinoma. Clin Nucl Med 2018;43:e422-e427.

20. Liu C, Liu T, Zhang N, Liu Y, Li N, Du P, Yang Y, Liu M, Gong K, Yang X, Zhu H, Yan K, Yang Z. 68Ga-PSMA-617 PET/CT: a promising new technique for predicting risk stratification and metastatic risk of prostate cancer patients. Eur J Nucl Med Mol Imaging 2018;45:1852-1861.

21. Demirci E, Kabasakal L, Şahin OE, Akgün E, Gültekin MH, Doğanca T, Tuna MB, Öbek C, Kiliç M, Esen T, Kural AR. Can SUVmax values of Ga68-PSMA PET/CT scan predict the clinically significant prostate cancer? Nucl Med Commun 2019;40:86-91.

22. Pollard JH, Raman C, Zakharia Y, Tracy CR, Nepple KG, Ginader T, Breheny P, Sunderland JJ. Quantitative Test-Retest Measurement of 68Ga-PSMAHBED-CC in Tumor and Normal Tissue. J Nucl Med 2020;61:1145-1152.

23. Jansen BHE, Cysouw MCF, Vis AN, van Moorselaar RJA, Voortman J, Bodar YJL, Schober PR, Hendrikse NH, Hoekstra OS, Boellaard R, Oprea-Lager DE. Repeatability of Quantitative 18F-DCFPyL PET/CT Measurements in Metastatic Prostate Cancer. J Nucl Med 2020;61:1320-1325.

24. Olde Heuvel J, de Wit-van der Veen BJ, Donswijk ML, Slump CH, Stokkel MPM. Day-to-day variability of [68Ga]Ga-PSMA-11 accumulation in primary prostate cancer: effects on tracer uptake and visual interpretation. EJNMMI Res 2020;10:132.

25. Onal C, Torun N, Akyol F, Guler OC, Hurmuz P, Yildirim BA, Cağlar M, Reyhan M, Ozyigit G. Integration of 68Ga-PSMA-PET/CT in Radiotherapy Planning for Prostate Cancer Patients. Clin Nucl Med 2019;44:e510-e516.

Kaynak Göster